Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07570082 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
A Phase 1 study, sponsored by Crinetics Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT07570082: Active Phase 1 study, sponsored by Crinetics Pharmaceuticals.
NCT07570082 is a Phase 1 study that is active but no longer recruiting, run by Crinetics Pharmaceuticals. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07570082, a Phase 1 study, is active but no longer recruiting, sponsored by Crinetics Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
Interventions
- DRUG Midazolam
- DRUG Metformin
- DRUG Atumelnant
- DRUG Digoxin
- DRUG Carbamazepine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT07570082 still lists
NCT07570082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT07570082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07570082 about?
NCT07570082 is a clinical study titled "Drug-Drug Interaction Study of Atumelnant in Healthy Participants". This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
What is the current status of trial NCT07570082?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2026-05-28. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07570082?
The interventions under investigation include: Midazolam (DRUG), Metformin (DRUG), Atumelnant (DRUG), Digoxin (DRUG), Carbamazepine (DRUG).
Who is sponsoring clinical trial NCT07570082?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07570082's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI